Undisclosed hepatocyte-expressed mRNA

Undisclosed hepatocyte-expressed mRNA is a placeholder designation used in pharmaceutical development to describe a proprietary genetic target located in liver cells. This terminology is frequently employed by biotechnology companies specializing in RNA therapeutics, such as Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, to protect intellectual property during the early stages of clinical trials [1][2]. The target typically involves a specific messenger RNA (mRNA) sequence that, when translated, produces a protein contributing to a disease state, such as a metabolic disorder, cardiovascular disease, or a rare genetic condition [3]. Therapeutic intervention usually involves the use of small interfering RNA (siRNA) or antisense oligonucleotides (ASOs) that are often conjugated with N-acetylgalactosamine (GalNAc) to ensure targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR) [4]. By binding to the target mRNA and inducing its degradation, these therapies prevent the synthesis of the pathogenic protein, thereby addressing the underlying cause of the disease [5]. This approach allows for the silencing of proteins that may lack traditional small-molecule binding sites but are accessible at the transcript level within the liver [4].

Other names

Undisclosed liver-expressed mRNAProprietary hepatocyte targetUndisclosed liver target

RNA interference (RNAi) or antisense oligonucleotide (ASO) mediated degradation of mRNA to inhibit protein translation.